(AOF) – NFL Biosciences, a biopharmaceutical company developing botanical drugs for the treatment of dependence and addiction, announces that it has filed a new patent application aimed at protecting the administration of NFL-101 in combination with other smoking cessation treatments and in particular nicotine substitutes. The application was originally filed in the United States and will be extended internationally in accordance with NFL Biosciences’ intellectual property protection strategy.
NFL Biosciences intends to demonstrate the benefit of combining NFL-101 with other smoking cessation treatments and in particular with nicotine substitute treatments.
Before the launch of dedicated clinical studies, NFL Biosciences filed a patent application to protect the administration of NFL-101 before an attempt to quit concomitant with the initiation of another smoking cessation treatment and particularly by nicotine replacement therapy. .
Nicotine substitutes include transdermal patches (patches), tablets, chewing gum, inhalers and nicotine spray. They are used as a substitute for cigarettes after stopping or reducing cigarette smoking to alleviate withdrawal symptoms due to stopping or reducing nicotine intake.
The global market for smoking cessation drugs is estimated at nearly $6 billion (source: Coherent Market Insights); with an estimated growth of 6% over the next few years, it is nevertheless limited by a lack of more effective treatments without side effects.
Despite a modest efficacy at 6 months, around 15.7% (source: EAGLES), nicotine substitutes represent 80% of the market. They are the reference treatments because they have no significant side effects and because other drugs such as Champix/Chantix and Zyban, which have slightly higher efficiencies, are sometimes poorly tolerated.
AOF – LEARN MORE
An inevitable race for new blockbusters
The patent for Merck’s star product, the cancer drug Keytruda, which accounts for more than 35% of its sales, expires in 2028. Despite the loss, since 2019, of the patents for its three star products (Avastin, Herceptine, Rituxan) Roche was able to renew its portfolio by bringing new molecules to market. However, the discovery and launch of new drugs are increasingly expensive. AstraZeneca spends about $6 billion a year on R&D in a pharmaceutical industry where the life of a patent only lasts ten to fifteen years. This leads laboratories to withdraw from certain activities. Thus J&J, Pfizer, GSK and, no doubt, Novartis soon prefer to refocus on specialty drugs and abandon any ancillary activity.